Latest From Biotech Now

Unraveling the Mystery of Alzheimer’s Disease

drew-headshot

Preeminent researchers from around the world gathered recently to tackle the science behind one of medicine’s toughest problems – Alzheimer’s – and elevating the disease as a top global priority. The Global CEO Initiative on Alzheimer’s Disease (CEOi) – a coalition of corporations from the fields of biotechnology, pharmaceuticals, diagnostics, finance, and healthcare – hosted a dinner during the Alzheimer’s Association International Convention (AAIC) in Boston. The CEOi had already taken strides to achieve this Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Separating Science from Fiction

The Atlantic recently published a story on the dangers of anti-vaccine rhetoric, “Destabilizing the Jenny McCarthy Public-Health Industrial Complex.” The article describes the hysteria around the alleged link between autism and vaccines, which has since been scientifically discredited. The public campaign created fear among parents, some of whom chose not to vaccinate their children. As the author states, “Anti-vaccinators risk not only the lives of their own children, but also those of others who are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

What’s Really Happening with the So-called ‘Blend Wall’? A Fuels America Briefing

Fuels-America-Briefing-July-11-Brent-1-300x200

The public dialog surrounding the Renewable Fuel Standard is robust- and filled with misinformation. On July 11, Rep. Lee Terry and Rep. Bruce Braley held the third of a series of briefings, which focused on what is really happening with the so-called ‘Blend Wall.’ The briefing consisted of five speakers, including BIO’s own Brent Erickson, Executive Vice President of the Industrial and Environmental Section. Opening remarks were given by Tom Buis, CEO of Growth Energy. Read More >

Biofuels & Climate Change  |  1 Comment  |  Email This Post
Tags: , , , , , , , , ,

BIO IP & Diagnostics Symposium

Final IPDX logo

BIO’s IP & Diagnostics Symposium (BIO IPDX) will review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. The program will review IP issues for both diagnostics generally and companion diagnostics. The program will also explore some of the potential regulatory dimensions. BIO aims to use this event to inform industry and government alike on how to move the science forward in the current climate. Where & Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Pivotal Role the Public Market Plays in Financing R&D

KennethMoch-Chimerix

Growing innovators are the heart of our industry. Biotech small businesses face a dual struggle – the daily challenge of running a growing company combined with the roadblocks intrinsic to groundbreaking scientific advancement. Innovative companies must overcome capital formation barriers in order to fund their next generation R&D.  The financing challenges that emerging biotechs face are unique, but we have the potential to save lives and treat patients in desperate need of hope. Today, I Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,